Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bendamustine
Drug ID BADD_D00230
Description Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Indications and Usage Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Marketing Status approved; investigational
ATC Code L01AA09
DrugBank ID DB06769
KEGG ID D07501
MeSH ID D000069461
PubChem ID 65628
TTD Drug ID D01CYA
NDC Product Code 68554-0050
UNII 9266D9P3PQ
Synonyms Bendamustine Hydrochloride | Hydrochloride, Bendamustine | Bendamustine | Bendamustin | Cytostasan | IMET 3393 | Ribomustin | Treanda | Zimet 3393
Chemical Information
Molecular Formula C16H21Cl2N3O2
CAS Registry Number 16506-27-7
SMILES CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Abdominal pain lower07.01.05.0100.000168%Not Available
Abdominal pain upper07.01.05.003--
Acidosis14.01.03.0020.000168%
Acute febrile neutrophilic dermatosis23.03.03.033; 01.02.01.0060.000224%Not Available
Acute hepatic failure09.01.03.0010.000224%Not Available
Acute myeloid leukaemia16.01.05.001; 01.10.05.0010.000660%Not Available
Acute myocardial infarction24.04.04.001; 02.02.02.0010.000280%Not Available
Acute respiratory distress syndrome22.01.03.001; 24.03.02.034; 10.02.01.067--
Acute respiratory failure22.02.06.001; 14.01.04.0040.000112%Not Available
Adenocarcinoma16.16.01.0040.000168%Not Available
Agranulocytosis01.02.03.0010.000392%Not Available
Anaemia01.03.02.0010.001287%
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000448%
Anaphylactic shock24.06.02.004; 10.01.07.0020.000224%Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.000112%
Anxiety19.06.02.002--
Aortic dissection24.02.03.002--Not Available
Aortic stenosis24.04.01.0010.000168%Not Available
Aortic valve incompetence02.07.03.0010.000168%Not Available
Aphasia19.21.01.001; 17.02.03.0010.000280%
Aphthous ulcer07.05.06.0020.000224%Not Available
Aplasia pure red cell10.02.01.003; 01.03.03.0010.000280%Not Available
Arrhythmia02.03.02.0010.000224%Not Available
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.04.011--
Asthenia08.01.01.0010.001119%Not Available
Ataxia17.02.02.001; 08.01.02.0040.000112%
Atelectasis22.01.02.0010.000448%
The 1th Page    1 2 3 4 5    Next   Last    Total 12 Pages